3.6 million neonatal deaths--what is progressing and what is not?

Joy E Lawn1, Kate Kerber, Christabel Enweronu-Laryea

  • 1Saving Newborn Lives/Save the Children-US, Cape Town, South Africa. joylawn@yahoo.co.uk

Seminars in Perinatology
|November 25, 2010
PubMed

Insights

Millions of newborns die annually, primarily from infections, preterm birth complications, and birth asphyxia. Improving data and implementing community-based interventions are crucial for reducing neonatal mortality globally.

Area of Science:

  • Global Health
  • Neonatal Medicine
  • Public Health Policy

Background:

  • Each year, 3.6 million infants die within the first four weeks of life (neonatal period), with most deaths occurring at home and remaining uncounted.
  • Neonatal mortality rates vary significantly by region, country, and even within countries, impacting progress towards global health goals.

Purpose of the Study:

  • To review global progress in newborn health, focusing on countries with the highest neonatal mortality rates.
  • To identify data availability for guiding accelerated efforts in newborn survival.
  • To summarize high-impact interventions for major causes of neonatal death and estimate their potential for saving lives.

Main Methods:

  • Review of global data on neonatal mortality trends and causes.
  • Analysis of regional and country-specific progress in reducing neonatal deaths.
  • Identification and summary of effective interventions for infections, preterm birth complications, and intrapartum-related neonatal deaths.

Main Results:

  • Global efforts show progress, but the rate of decrease in neonatal mortality differs across regions and countries.
  • Infections, preterm birth complications, and intrapartum-related neonatal deaths (birth asphyxia) constitute over 80% of all neonatal deaths.
  • Significant reductions are noted for neonatal tetanus and apparent progress in reducing infections, while reductions in preterm birth and intrapartum-related deaths remain limited.

Conclusions:

  • While progress is being made, substantial gaps remain in reaching mothers and newborns during birth and the early postnatal period.
  • Promising community-based service delivery models are being adapted and evaluated at scale, particularly in Asia and Africa.
  • Improving the quantity, quality, and utilization of data is critical for selecting effective interventions and strengthening neonatal health programs, especially at the district level.

Related Concept Videos

Methods Of Healthcare Delivery System01:26

Methods Of Healthcare Delivery System

At the different levels of the healthcare system, we see varying methods of healthcare used. These methods include managed care systems, case management, and primary healthcare.
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is limited...
International Nursing Organizations II01:28

International Nursing Organizations II

The World Health Organization (WHO) is a specialized agency of the United Nations based in Geneva. The WHO has many initiatives that center around health. Primarily, they lead global efforts to expand universal health coverage using science-based policies and programs. They are also responsible for shaping health research agendas and developing norms and standards.
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: